Mucosal immune responses to meningococcal C polysaccharide-protein conjugate in mice.
Mucosal delivery of vaccines represents an attractive approach because this is a region of first contact point for inhaled antigens. We have obtained a meningococcal group C polysaccharide-tetanus toxoid conjugate (MGCP-TT) and evaluated it for intranasal route in mice. The conjugate was obtained by a developed method in our laboratory. The specific IgA in saliva and specific IgA and IgG in serum were measured by ELISA methods and bactericidal antibodies in sera against a meningococcal group C strain were measured. The conjugated elicited a significant increase in anti-MGCP salivary IgA and serum IgG and bactericidal antibodies concentrations, while specific serum IgA was not observed. These results indicated that after conjugation, there was a change in the responses for MGCP from thymus-independent to thymus-dependent and that it was effective by intranasal route.
Cuello
Maribel
M
Immunology Department, Finlay Institute, 27 Avenue No. 19805, P.O. Box 16017, Havana, Cuba. mcuello@finlay.edu.cu
Cabrera
Osmir
O
del Campo
Judith M
JM
Parajón
Elina
E
Sotolongo
Franklin
F
Camaraza
Maria A
MA
Arnet
Aida
A
Suárez
Magaly
M
Pérez
Oliver
O
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D018928:Immunity, Mucosal; D022401:Meningococcal Vaccines / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009345:Neisseria meningitidis; D013745:Tetanus Toxoid / Q000737:chemistry / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000276:immunology
D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate; C410218:serogroup C meningococcal conjugate vaccine